Altered Heterogeneity of Ageing Lung Endothelium is a

Hallmark of Idiopathic Pulmonary Fibrosis

Eamon C. Faulkner ¹, Adam A. Moverley ², Simon P. Hart ^{3*} and Leonid L. Nikitenko ^{1*}

¹ Centre for Biomedicine, Hull York Medical School, University of Hull.

 2 Department of Cell and Developmental Biology, University College London.

³ Respiratory Research Group, Hull York Medical School, University of Hull.

* These authors share senior authorship.

Corresponding author:

Leonid L. Nikitenko PhD DSc, Room 202, Allam Building, Centre for Biomedicine, Hull York Medical School, University of Hull, Hull, HU6 7RX. Tel +44(0)1482 462062; leonid.nikitenko@hyms.ac.uk

Running title:

Heterogeneity of ageing endothelium in IPF.

Keywords:

Ageing lung, endothelial cell, idiopathic pulmonary fibrosis, lymphatic, single cell RNA sequencing.

Supplementary information:

Additional files 1-4.

¹**Abstract**

2

Background
4 Older age is

⁴Older age is the main risk factor for chronic lung diseases including idiopathic pulmonary 5 fibrosis (IPF). Halting or reversing progression of IPF remains an unmet clinical need due to
6 limited knowledge of underlying mechanisms. The lung circulatory system, composed of 6 limited knowledge of underlying mechanisms. The lung circulatory system, composed of
7 blood (pulmonary and bronchial) and lymphatic vessels networks, has been implicated in IPF ⁷blood (pulmonary and bronchial) and lymphatic vessels networks, has been implicated in IPF 8 pathophysiology in elderly people, based solely on reports of altered density and increased 9 permeability of vessels.

¹⁰**Aim**

11 We aimed to define heterogeneity and IPF-associated changes of lung endothelial cells (EC
12 or endothelium) by comparing gene expression in tissues from elderly people - transplant

¹²or endothelium) by comparing gene expression in tissues from elderly people - transplant

13 donors and recipients with IPF.
14 **Methods**

¹⁴**Methods**

¹⁵Single-cell RNA sequencing (scRNAseq) datasets of "ageing lung" tissues were selected only 16 from those publicly available sources that contain age-matching samples for both groups (49-
17 77 vears old donors and IPF patients: nine pairs in total), integrated and compared. Findings ¹⁷77 years old donors and IPF patients; nine pairs in total), integrated and compared. Findings 18 were validated by immunohistochemistry using EC-specific markers.
19 **Results**

¹⁹**Results**

²⁰The generation of integrated single-cell maps of ageing lung tissues revealed 17 21 subpopulations of endothelium (12 for blood and 5 for lymphatic vessels, including 9 novel), 22 with distinct transcriptional profiles. In IPF lung, the heterogeneity of ageing lung
23 endothelium was significantly altered - both in terms of cell numbers (linked to disease-23 endothelium was significantly altered - both in terms of cell numbers (linked to disease-24 related changes in tissue composition) and differentially expressed genes (associated with
25 fibrosis, inflammation, differentiation and vasodilation) in individual pulmonary, bronchial ²⁵fibrosis, inflammation, differentiation and vasodilation) in individual pulmonary, bronchial 26 and lymphatic EC subpopulations.

²⁷**Conclusions**

²⁸These findings reveal underappreciated extent of heterogeneity and IPF-associated changes of 29 ageing lung endothelium. Our data suggest direct involvement of specific subpopulations of
20 ageing lung endothelium in IPF pathophysiology, uncovering cellular and molecular targets ageing lung endothelium in IPF pathophysiology, uncovering cellular and molecular targets 31 which may have potential diagnostic, prognostic and therapeutic relevance. This study creates
32 a conceptual framework for appreciating the disease-specific heterogeneity of ageing lung a conceptual framework for appreciating the disease-specific heterogeneity of ageing lung ³³endothelium as a hallmark of IPF.

³⁵**Background**

36 Increasing age is the main risk factor for diagnosis and prognosis of major non-37 communicable lung diseases, including lung cancer, chronic obstructive pulmonary disease 38 (COPD) and idiopathic pulmonary fibrosis (IPF) $[1, 2]$. IPF is the most common, progressive 39 and lethal interstitial lung disease with a prevalence of 33 to 450 per million people globally ⁴⁰[3]. IPF progression leads to declining quality of life, respiratory failure and eventually lung 41 transplantation or death. While the number of older people suffering from this disease is ⁴²steadily increasing and histopathological pattern of usual interstitial pneumonia (UIP), 43 hallmarks of ageing, particularly cellular senescence and extracellular matrix (ECM) 44 dysregulation, are prominent in the IPF lung, the aetiology of this disease remains unclear $[2, 1]$ ⁴⁵4-7]. Detailed understanding of cellular and molecular mechanisms underlying IPF-⁴⁶associated changes in ageing human lung will be essential for diagnostics or prognostics of ⁴⁷IPF, and for developing effective therapies to halt or reverse disease progression.

⁴⁸Several lines of evidence implicate a role for the circulatory system, composed of blood 49 (pulmonary and bronchial) and lymphatic vessel networks, in IPF $[7-18]$. Some studies report ⁵⁰structural or functional changes in blood or lymphatic vessels, which are lined with a 51 monolayer of endothelial cells (EC or endothelium), although often without a comparison 52 between IPF patients and age-matched controls $[10, 15, 17]$. The precise contribution of 53 specialized lung vessel subtypes [19, 20] and distinct EC subpopulations that comprise them 54 to the pathophysiology and progression of IPF remain insufficiently characterized $[21, 22]$.

55 Recent advances in single-cell RNA sequencing (scRNAseq) [23] have allowed ⁵⁶characterisation of cellular heterogeneity in healthy and diseased lung, resulting in the 57 generation of a human lung cell atlas (HLCA; $[22]$) and the IPF cell atlas $[24]$. Studies of 58 heterogeneity of human lung endothelium have reported up to nine subpopulations of EC in 59 healthy and/or diseased lung $[22, 25, 26]$. These reports utilised data from either a diverse 60 population of subjects (patients with COPD, IPF or other lung diseases, commonly placed

61 together for comparison) with a range of ages (varying from 21 to 80 years in some cases), 62 ethnicities and tobacco smoker statuses, or used samples from different areas of the lung, e.g. 63 distal lung parenchyma $[27]$, longitudinal sections $[25]$ or multiple lobes $[28]$. One recent ⁶⁴study generated a cell atlas of ageing lungs in COPD, comparing age-matched healthy 65 subjects and patients, and identifying 6 subpopulations of EC [21]. However, currently there ⁶⁶is still a major gap in knowledge about properties and roles of individual cell subpopulations 67 composing ageing human lung endothelium in other chronic lung diseases, including IPF. ⁶⁸Our report is the first to define (characterize, compare and contrast) the heterogeneity and 69 disease-associated changes of ageing lung endothelium in IPF patients and age-matched older 70 healthy subjects. 71 ⁷²**Results** 73 ⁷⁴**Integrated Single Cell Map of Ageing Human Lungs Displays Endothelial Cell** ⁷⁵**Contribution in Disease** ⁷⁶To characterise ageing human lung endothelium in IPF and to account for its intra- and 77 inter-lung heterogeneity within and between individuals [29], we performed comparative 78 analysis of scRNAseq data from lung tissue samples selected only from age-matched ($63±14$) 79 years old) transplant donors and recipients with IPF. Specifically, we selected data from only

80 those studies (cohorts) that contained samples for both conditions (transplant donors and IPF 81 patients). From all publicly available scRNAseq datasets of human IPF lungs (4 in total, to 82 our knowledge; [25, 27, 28, 30, 31]), only two, representing independent cohorts of 83 subjects/individuals of different ethnic backgrounds, with controlled sample locations, 84 fulfilled these selection criteria $[25, 27]$ and therefore were used for generating a single 85 dataset of ageing human lungs for integrative comparative scRNAseq analysis (Table 1;

⁸⁶Figure 1A; for full details on dataset selection see Additional file 1: Detailed methods /

87 Dataset Selection).

88 The integration of the two datasets resulted in generation of a multi cohort single cell map 89 revealing 25 distinct populations (Figure 1A-B, Additional file 2: Figure S1), based on ⁹⁰specific gene expression patterns (Figures 1C, Additional file 2: Figure S2, Additional file 3: 91 Table S1) that include known cell type-specific transcriptomic markers $[22, 25-27]$. Identities 92 of two closely related blood and lymphatic vessel EC (BEC and LEC respectively) 93 populations (Figure 1B) were confirmed by detailed analysis of expression of a panel of pan-⁹⁴EC and lymphatic EC-specific markers (Figure 1D).

95 Quantitative analysis of cell numbers for each of 25 populations in age-matched groups 96 revealed IPF-associated changes in ageing human lungs in both cohorts (Figure 1E). The 97 analysis reflected differences in location of tissue samples (Table 1), matching contribution 98 of different cell types to the total human lung cell population and alterations in IPF lung 99 reported in age non-matching studies $[21, 22, 25-27, 30, 32]$ (Additional file 3: Table S2). ¹⁰⁰Also, it uncovered statistically insignificant changes in proportions of ageing human lung 101 BEC and LEC populations between cohorts and conditions (Figure 1E, Additional file 3: 102 Table S3), which is in agreement with similar analysis in age non-matching study of IPF ¹⁰³lungs [25]. Data integration revealed comparable spatial profiles of ageing human lung EC 104 populations in two conditions and two cohorts (Figure 1F) and their similar contribution in 105 donors and IPF patients (Figure 1G).

¹⁰⁷**Blood Vessel Endothelium in Ageing Human Lung Exhibits Disease-Specific** ¹⁰⁸**Heterogeneity and Alterations in Cell Numbers of Individual Subpopulations**

109 Unsupervised clustering of ageing human lung BEC alone (n=3192) identified 12 distinct 110 subpopulations (Figures 1A, 2A) based on their differentially expressed genes (DEG; Figures ¹¹¹2B, Additional file 2: Figure S3). Expression analysis of pan-EC markers and LEC-specific

112 genes confirmed their identities as BEC (Figure 2C). The analysis of top 10 DEG for each 113 subpopulation (110 in total) determined their selection for inclusion (or not) in 10 signatures 114 of ageing human lung BEC subpopulations (Figures 2B, D, Additional file 2: Figure S3, S4; 115 Additional file 3: Figure Table S4). 49 selected subpopulation-specific DEG contribute to 116 distinct transcriptional profiles for subpopulations 1-4 and 6-11 (Figure 2D). Subpopulations 117 zero and 5 lack obvious markers or signatures (Figures 2D, Additional file 2: Figure S5).

¹¹⁸Expression analysis of the 49 subpopulation-specific DEG (Figure 2D) in the total lung 119 revealed that the majority of them were not EC-specific, i.e. also expressed in other cell types ¹²⁰(Additional file 2: Figure S4A). 39 of them have not been previously assigned as markers of 121 8 generic subpopulations of BEC identified and characterised earlier in human or mouse lung ¹²²[21, 22, 25, 26, 33], and thus are newly associated with ageing human lung endothelium ¹²³(Figure 2D; Additional file 2: Figure S4A, B). A pathway analysis uncovered their belonging 124 to specific classes of proteins, including secreted molecules, cell surface receptors, 125 transcription factors and sub-cellular distribution (Additional file 2: Figure S4B-C).

¹²⁶Three-dimensional pseudo-time lineage analysis revealed close relationships between 127 identified BEC subpopulations (Figure 2E; Additional file 4: Video S1). This included a 128 direct link between subpopulations 5 and 3, and manifestation of subpopulation zero as a 129 "convergence point" for seven subpopulations - 1, 2, 4, 6, 9, 10, 11 and, partially, 8. The 130 expression analysis of markers of EC sub-types proposed in other transcriptional studies in 131 human and murine lungs [21, 26, 33-38] was applied to 12 ageing human lung BEC 132 subpopulations identified in our study, and revealed only few distinct "marker / ageing 133 human lung BEC subpopulation" matches (Additional file 2: Figures S6, S7). Further ¹³⁴exploration of identities of 12 subpopulations by using these markers and also those proposed 135 for specific EC subpopulations in HLCA and IPF cell atlas studies $[21, 22, 24-26]$, when 136 coupled with module scoring (Figure 2F) and cell cycle (Additional file 2: Figure S8) 137 analyses, confirmed these findings, whilst 4 subpopulations (zero, 5, 10 and 11) remained un-

¹³⁸matched (Figures 2F). Finally, quantitative analysis revealed a significant increase in 139 representation of two subpopulations (1 and 2) and overall decrease in subpopulation 7 in IPF ¹⁴⁰(Figure 3A-C; Additional file 3: Tables S5, S6), with specificity by the cohort (Figure 3D).

¹⁴²**Annotation of Blood Vessel Endothelial Cell Subpopulations and Identification of**

¹⁴³**Dedifferentiated Cells in Ageing Human Lung**

144 Altogether, our findings formed the foundation for the annotation of 12 ageing human lung ¹⁴⁵BEC subpopulations with distinct transcriptional signatures (Figure 4A; in-depth description 146 is provided in Additional file 1: Detailed methods, Annotation of BEC subpopulations). ¹⁴⁷Integrative analysis revealed that ageing human lung BEC belong to three and 8 ¹⁴⁸subpopulations of bronchial and pulmonary circulation networks respectively (with one, 149 inflammatory, being "intermediary" as also identified in other reports $[24]$), and include two 150 previously undescribed subpopulations - designated as "de-differentiated" endothelium - in 151 pulmonary circulation (Figures 4A, 2F, Additional file 2: Figure S9). Ten subpopulations of 152 ageing human lung BEC have distinct transcriptional signatures, whilst no obvious DEG 153 could be identified for subpopulations zero and 5 (Figures 2B, 2D, 4A, Additional file 2: ¹⁵⁴Figures S5, S11; in-depth description is provided in Additional file 1: Detailed methods, 155 Annotation of BEC subpopulations).

156 Subpopulations zero, 5, 10 and 11 had similar expression levels and ridgeplot profiles ¹⁵⁷(histograms) to all other BEC subpopulations for the housekeeping gene beta-2 ¹⁵⁸macroglobulin (B2M; Figure 2D; Additional file 2: Figure S12A). These subpopulations also 159 exhibited low, but similar in ridgeplot profiles to other BEC subpopulations, expression of 160 pan-EC genes (Figure 2C-D, Additional file 2: Figure S15A, B). Subpopulations zero and 5 161 contained a lower average number of genes per cell compared to other BEC subpopulations ¹⁶²(Additional file 2: Figure S12B) and did not express markers of 23 non-EC cell clusters of

¹⁶³human lung (Additional file 3: Table S1; Additional file 2: Figure S12C) or EC progenitors

164 (Additional file 2: Figure S12D).

165 Next, we used these novel identified signatures (Figure 4A) to test the hypothesis that BEC 166 subpopulation zero (the largest one in donor group in integrated dataset; Figure 3C) is 167 exclusively associated with ageing in the human lung. The comparison of scRNAseq datasets 168 of four ageing and three non-ageing/young human lungs against these signatures led to 169 annotation of BEC subpopulations in both age groups (Additional file 2: Figures S13, S14). ¹⁷⁰All signatures, except for subpopulations 1 and 2 (bronchial venules IPF Endo 1 and 2, which 171 are noticeably associated mainly with ageing IPF lung in cohorts 2 and 1 respectively; Figure ¹⁷²3C-D), were matching specific subpopulations in both age groups (as expected, since these 173 were donor lung samples, Additional file 2: Figure S14E). Cell number analysis revealed that ¹⁷⁴BEC subpopulation zero (identified as subpopulation A in ageing vs non-ageing/young lung 175 analysis), which has no obvious DEG, was present within ageing human lung only ¹⁷⁶(Additional file 2: Figures S13B-C, S14E), supporting our hypothesis and its annotation as an 177 ageing-related "de-differentiated" BEC (Figure 4A).

¹⁷⁸Finally, unsupervised hierarchical clustering of 12 subpopulations of ageing human lung ¹⁷⁹BEC revealed two distinct groups - "capillary/microvascular" and "macrovascular" (Figure ¹⁸⁰4B). In IPF, the relationships between subpopulations were altered, with "bronchial 181 venule/IPF Endo 1" and "intralobular venule" subpopulations "translocating" to "capillary/ 182 microvascular" (Figure 4B).

¹⁸⁴**Cell Numbers for Bronchial Blood Vessel Endothelial Cell Subpopulations in Ageing** ¹⁸⁵**Distal Lung Depend on Fibrosis Degree and Bronchi Number in IPF**

186 To investigate the reason for differential cell numbers observed for two bronchial BEC 187 subpopulations (2 and 7; bronchial venule and capillary BEC respectively) in IPF (Figure 3C, ¹⁸⁸D), we focused on analysing scRNAseq data from the distal part of human ageing lungs

¹⁸⁹(cohort 1; four donors and four IPF patients; Figure 5 A, B). This analysis exposed 190 considerable variation in a percentage of subpopulation 2 cells between individual samples in ¹⁹¹IPF (5.48 - 91.6 %), suggesting inter-lung sample heterogeneity. The comparison of 192 scRNAseq data with IPF lungs histology (based on haematoxylin and eosin staining) for each ¹⁹³individual case, which has been made available by the authors in the supplementary materials 194 section of the original study $[27]$, revealed that the lowest percentage of subpopulation 2 cells 195 was detected in sample IPF04, where there was a noticeable lack of bronchial structures. 196 Based on these findings, we hypothesised that in IPF lung, significantly altered heterogeneity ¹⁹⁷(in terms of differential cell numbers) of ageing bronchial (and also possibly pulmonary and ¹⁹⁸lymphatic) endothelium reflects association with histological changes, i.e. tissue composition, 199 and, in particular, with the increase in percentage of (i) areas occupied by peri-bronchial 200 spaces undergoing fibrotic alterations and/or (ii) a number of bronchi, in particular, which 201 both underpin inter- and intra-lung heterogeneity in IPF.

²⁰²To test this hypothesis, we analysed a distal lung surgical diagnostic lung biopsy from a ²⁰³58-year-old male patient with IPF, confirmed by a histopathological pattern of UIP. First, we 204 identified 8 BEC subpopulations, including 2 and 7, by spatial position/localisation in ageing 205 human lung tissue of EC by immunostaining using two pan-endothelial (for various human 206 tissues, including lung) markers - platelet endothelial cell adhesion molecule (*PECAM-1*), 207 also known as cluster of differentiation 31 (CD31; $[41]$) and calcitonin receptor-like receptor ²⁰⁸(CLR, encoded by *CALCRL* gene; [42-44]; see also Figure 1D) (Additional file 2: Figure ²⁰⁹S15). Next, image analysis allowed quantification of IPF-associated changes in cell numbers 210 for subpopulations 2 and 7 (Figure 5C-I). The comparative analysis of low vs high degree 211 fibrotic areas within peri-bronchial regions in distal lung parenchyma identified no 212 differences in the number of CLR-positive nuclei in venules (vessel diameter $>7\mu$ m) and a 213 significant decrease in capillaries (vessel diameter $\langle 7\mu m;$ Figure 5C-E; Additional file 2: ²¹⁴Figure S16), reflecting BEC from subpopulations 2 and 7 respectively, between groups.

²¹⁵Furthermore, comparative analysis of sections from two different areas of a distal lung 216 parenchyma from the same IPF patient revealed the association of percentage of CLR-217 positive nuclei for both capillaries and venules with the number of bronchi (Figure 5F-I; 218 Additional file 2: Figure S17).

219 Altogether, these findings from immunohistochemistry corroborated the scRNAseq 220 analysis of IPF-associated changes in cell numbers of bronchial BEC subpopulations 2 and 7 221 in distal lung parenchyma in four IPF patients from cohort 1. Importantly, it revealed the ²²²association of changes in cell numbers of ageing human BEC subpopulations 2 (venules) and ²²³7 (capillaries) in peri-bronchial areas with the fibrosis degree and bronchi number.

²²⁵**scRNAseq and Immunohistochemistry Reveal Fibrotic Alveolar Regions as Potential** ²²⁶**Niches for Dedifferentiated Blood Vessel Endothelial Cell Subpopulations in IPF**

227 To investigate the possible location of BEC subpopulation zero in IPF, we focused on 228 analysing scRNAseq data from the distal part of human ageing lungs (cohort 1; four donors 229 and four IPF patients; Figure 6A). This exposed a noticeable variation in a percentage of cells 230 between individual samples in IPF (3.79 - 73 %; Figure 6A), suggesting their inter-lung 231 heterogeneity (similar to findings for BEC subpopulation 2; Figure 5B), and revealing a ²³²negative correlation between subpopulations zero and two (Figure 6B). Interestingly, the 233 highest percentage of subpopulation zero cells was detected in the sample IPF04 (Figure 6C), 234 which according to histology of individual IPF lungs (based on haematoxylin and eosin ²³⁵staining) for each individual case, which has been made available by the authors in the 236 supplementary materials section of the original study ($[27]$), was associated with the lack of 237 bronchial structures. Based on these findings and association of subpopulation zero with 238 pulmonary circulation (4A; based on negative score for bronchial circulation signature, ²³⁹Figure 2F), we hypothesised that BEC subpopulation zero resides mainly in the alveolar

240 regions or "niches" of the distal part of human ageing lungs in IPF, where it is likely to derive

241 from BEC subpopulations 3, 4, 6 or 8 (Figures 2A, E, 3D and 4A).

242 To test this hypothesis, scRNAseq data analysis was focused on distal ageing human lung 243 samples (cohort 1), revealing that the increase in percentage of subpopulation zero cells in ²⁴⁴IPF lungs was associated with a decreased in percentage of alveolar subpopulations 3, 4, 6 or ²⁴⁵8 BEC, when they are analysed together, as a "single alveolar pool" in ageing human lung ²⁴⁶(Figure 6D). Interestingly, subpopulation zero has expression profiles for housekeeping gene ²⁴⁷B2M (Figure 1B, Additional file 2: Figure S12A) and pan-EC markers (*PECAM1*/CD31 and 248 *CALCLR*/CLR) (Additional file 2: Figures S15A, B) comparable to all other ageing human 249 lung BEC subpopulations, whilst having a considerably larger proportion of cells with lower 250 expression of the latter two genes. Furthermore, quantitative analysis of *PECAM1* expression 251 in donor and fibrosis samples confirmed similarities in ridgeplot profiles between 252 subpopulation zero and alveolar BEC subpopulations 3, 4, 6 and 8 (in terms of presence of 253 both *PECAM1* positive and negative cells, as well as a trend for increased number of ²⁵⁴*PECAM1* negative cells in fibrosis; Figure 6E, top and middle panels). Integrative analysis of 255 alveolar BEC subpopulations $(3, 4, 6 \text{ and } 8)$ and subpopulation zero taken together, as a 256 "single alveolar pool" in ageing human lung, revealed the trend for a reduction of *PECAM1* ²⁵⁷expression (reflected by the decrease in percentage of positive cells) in fibrosis, also linked to 258 an increased variability between individual samples (Figure 6E, bottom panel). 259 Immunohistochemistry and image analysis of CD31 expression in distal alveoli in IPF lung 260 revealed a statistically significant decrease in proportion of CD31-positive nuclei and CD31 261 signal intensity in fibrotic compared to non-fibrotic alveoli (Figure 6 F-H; Additional file 2: ²⁶²Figure S18). Combining analysis of *PECAM1/*CD31 expression by scRNAseq and 263 immunohistochemistry revealed similar decreases in expression (compare last graphs in ²⁶⁴Figures 6E and H), thus supporting our hypothesis that BEC subpopulation zero resides 265 mainly in the alveolar regions/niches of the distal part of human ageing lungs in IPF.

266

²⁶⁷**Expression of Genes Linked to Disease-Specific Signalling Pathways and Endothelial**

²⁶⁸**Cell Processes is Altered in Ageing Lung Blood Vessel Endothelium in IPF**

269 Comparison of gene expression between donor and IPF lungs led to identification of 3596 270 significantly regulated (1600 down- and 1996 up-) DEG across 12 BEC subpopulations ²⁷¹(Figures 7A-B, Additional file 2: Figure S19A; Additional file 3: Table S7). There were 272 significant associations with specific signalling pathways in 7 (two bronchial and 5 273 pulmonary, including two "de-differentiated") from 12 subpopulations (Figure 7C). DEG in 274 subpopulations zero, 8 and 11 were directly linked to IPF-associated pathways, and in four 275 others $(1, 3, 5 \text{ and } 11)$ - with fibrotic or inflammatory pathways (Figures 7C, Additional file 276 2: Figure S19B). Next, the utilisation of published gene set enrichment analysis (GSEA) 277 libraries for the assessment of expression of marker genes which are associated with ten EC-278 relevant processes revealed positive module scores in 5-12 of the BEC subpopulations for 279 individual processes on average (Additional file 2: Figure S20) and significant changes in 280 several (3 bronchial and 6 pulmonary, including two "de-differentiated") BEC 281 subpopulations in IPF (Figure 7D-E). This reflected subpopulation-specific pattern of 282 endothelium response to the fibrotic lung environment in all processes, ranging from two (for 283 senescence) to 8 (for vasodilation) subpopulations amongst 9 analysed (Figures 7E).

²⁸⁵**Integrated Single Cell Map and Immunohistochemistry of Ageing Human Lung** ²⁸⁶**Lymphatic Endothelium Reveal Its Heterogeneity and Contribution in IPF**

²⁸⁷Unsupervised clustering of subtracted ageing human lung LEC alone in integrated dataset ²⁸⁸(689 cells) identified two main populations consisting of five distinct, and to our knowledge 289 previously uncharacterised, subpopulations in total (Figures 1A, 8A), as based on their DEG 290 patterns (top 10 DEG for each, 50 in total, with 20 not associated with LEC formerly $[22, 26]$ ²⁹¹(Figures 8B-D; Additional file 2: Figure S21, 22F) and cell cycle analysis (Additional file 2:

²⁹²Figure S23). All signatures were specific in recognising individual LEC subpopulations 293 (Additional file 2: Figure S21A-B). Intriguingly, ageing human lung LEC subpopulations 1 294 and 2 were present only in cohort 1 and subpopulations zero, three and $4 -$ exclusively in 295 cohort 2 (Additional file 2: Figure S24). Quantification of cell numbers revealed a trend for a ²⁹⁶decrease (for subpopulations 1 and 2) but overall a lack of non-significant changes for all 297 subpopulations between donor and IPF lungs in integrated (Additional file 2: Figure S24A-B; ²⁹⁸Additional file 3: Table S9) or percentage contribution when split by cohort (Additional file ²⁹⁹2: Figure 24C-E; Additional file 3: Table S9) datasets, in contrast to cell number data on BEC ³⁰⁰(Figure 3C, D). Altogether, our findings formed the foundation for detailed transcriptional 301 characterisation of five distinct (informed by DEG, our transcriptional signatures, sample 302 collection site and cell cycle information) LEC subpopulations in ageing human lung (Figure ³⁰³8D; in-depth description is provided in Additional file 1: Detailed methods, Annotation of 304 LEC Subpopulations).

305 To investigate the reason for non-differential cell numbers observed for ageing human ³⁰⁶LEC in IPF (Additional file 2: Figure S24), compared to differential cell numbers observed 307 for two bronchial BEC subpopulations (2 and 7), we focused scRNAseq data analysis on two ³⁰⁸LEC subpopulations (1 and 2) detected in the distal part of human ageing lungs from four 309 donors and four IPF patients (cohort 1; Figure 8E). This exposed very small variation in a 310 percentage of subpopulation 2 (PDPN-positive) cells between individual samples in IPF (0.71 ³¹¹- 5.20%; Figure 8E), contrasting findings for BEC subpopulations zero, two and 7 (Figures 312 5B and 6A, C). Based on this observation and on histology from 4 previous reports, jointly 313 covering 5 different structures in ageing lung in donors or IPF patients $[9, 11, 26, 46]$, we ³¹⁴hypothesised that PDPN-positive LEC are distributed uniformly in all tissue regions ³¹⁵(bronchial and alveolar) within ageing human distal lung parenchyma in IPF.

316 For testing this hypothesis, we immunostained human IPF lung tissue using anti-PDPN 317 antibody D2-40 (Figure 8 F, G). The quantification analysis of immunostaining in this distal

³¹⁸lung parenchyma sample uncovered signs of developing fibrosis and substantial intra-lung 319 heterogeneity throughout the section areas/regions and revealed the distribution of PDPN-320 positive vessels (Additional file 2: Figure S25). Interestingly, the comparison to inter-lung 321 heterogeneity, which was detected across four samples within cohort 1 (as demonstrated by 322 histological analysis using haematoxylin and eosin staining; $[27]$) and cohort 2 (as 323 demonstrated by immunohistochemistry images presented by the authors; $[25]$) detected the 324 presence of all identifiable structures from both cohorts (non-fibrotic and fibrotic alveolae, 325 bronchiole and honeycomb cyst in cohort 1; and large artery and veins, bronchiole and pleura 326 in cohort 2) within the surgical distal lung biopsy. It also revealed uniform distribution of ³²⁷PDPN-positive LEC nuclei in all detected tissue regions (bronchial, alveolar and pleural) 328 within ageing human distal lung parenchyma and honeycomb cyst regions (Figure 8 F-G; 329 Additional file 2: Figure S25). Together with finding from scRNAseq data analysis, which 330 showed that in ageing human lung PDPN-positive LEC subpopulation 2 was present only in 331 cohort 1, whilst PDPN-positive LEC subpopulations zero and 4 - exclusively in cohort 2 ³³²(Figure 8C), these data suggest that our immunostaining detected all three subpopulations of ³³³PDPN-positive LEC subpopulations (zero, two and 4) in ageing human lung in IPF within 334 our single diagnostic biopsy (Figure 8 F-G).

335 Next, high content image quantification of cell numbers/percentage of cells revealed 336 uniform percentages of PDPN-positive LEC across analysed bronchial, alveolar and 337 subpleural regions, including both fibrotic and non-fibrotic regions (ranging from 4.5% to 338 20.9%; Figure 8 H; Additional file 2; Figure S25). These findings support scRNAseq analysis 339 data, which revealed lack of significant differences for these subpopulations in IPF lungs in 340 the integrated dataset (Additional file 2: Figure S24A-B; Additional file 3: Table S9), thus 341 supporting our hypothesis.

³⁴²Finally, gene expression comparison between donor and IPF lungs led to identification of ³⁴³101 significantly up-regulated DEG across 5 LEC subpopulations (Figures 8I), compared to

³⁴⁴3596 DEG for ageing human ling BEC (Figure 7B) and significant linkage to IPF-associated 345 pathways in subpopulations zero and one (Additional file 2: Figure S26). Finally, the 346 utilisation of GSEA libraries identified significant alterations in ageing human lung LEC, in 347 IPF (Figure 8J; Additional file 2: Figure S26 C-L).

³⁴⁹**Discussion**

350 The role of the lung circulatory system, including both blood and lymphatic vessel networks, 351 has been implicated in IPF pathophysiology, but subpopulations of endothelium in ageing 352 human lung and their disease-specific properties remained insufficiently characterized. ³⁵³Previous studies aimed at generating cellular atlases have predominantly used diverse 354 datasets from healthy donors and patients with different diseases covering a wide range of 355 ages, ethnicities and other characteristics [22, 25-27, 30, 32]. This complicated the 356 deconvolution of a highly heterogeneous population of specialized cells in human lung and ³⁵⁷detection of changes triggered by the ageing process itself, as well as additional alterations 358 caused by individual age-associated diseases. We generated a first integrated (multi-cohort) ³⁵⁹map of individual cell populations in ageing human lung in IPF and identified the 360 contribution of blood and lymphatic vessels endothelium. This resource can be used as a 361 foundation for identifying and studying ageing endothelium in other age-associated chronic 362 lung diseases.

363 The identification and annotation of 17 subpopulations of endothelium (12 BEC and 5 ³⁶⁴LEC), with distinct molecular signatures and percentage contribution in ageing human lung ³⁶⁵in donors and IPF patients, is of particular significance. Integrated single-cell maps of the 366 ageing human lung endothelium advanced resolution of BEC and LEC populations, 367 increasing the number of formerly identified in ageing human lung EC subtypes [21, 22] ³⁶⁸from 9 to 17 and revealing previously underappreciated extend of their diversity and 369 heterogeneity, especially in distal lung. Apart from confirming the presence of three

370 bronchial and 8 pulmonary, as well as one "intermediary" (inflammatory), subpopulations, 371 our integrative analysis detected four to our knowledge previously uncharacterised 372 subpopulations of BEC in ageing human lung, when compared to previous scRNAseq reports ³⁷³[21, 22, 24]. Spatial validation based on immunohistochemistry using pan-EC markers 374 confirmed the presence of 8 of these 12 BEC subpopulations in the distal ageing human lung. 375 Our study also revealed the existence of 5 subpopulations of ageing LEC by transcriptional 376 analysis. DEG signatures for 17 subpopulations of ageing human lung endothelium contain ³⁷⁷59 novel subpopulation-specific candidate genes (39 for BEC, 20 for LEC). The pathway 378 analysis of these DEG provides a springboard for exploring their roles and potential as 379 biomarkers for diagnostics and/or prognostics in IPF.

380 Our study identified two BEC subpopulations (10 and 11, "Pneumocyte marker (low) ³⁸¹expressing" and "Immune marker (low) expressing" respectively) in both the young and the 382 ageing human lung. These subpopulations have been previously characterised in murine and 383 porcine models $[47-49]$, but to our knowledge have not been yet identified in the human lung. ³⁸⁴The pneumocyte marker (low) expressing subpopulation had been found in the context of 385 pulmonary hypertension or obesity in mice $[47, 48]$ and surfactant proteins have been 386 detected in the circulation in IPF $[50, 51]$. The immune marker (low) expressing 387 subpopulation had been found in porcine vasculature via generation of a multiple-organ 388 single-cell transcriptomic map [49]. In human lung, these cells express markers of EC 389 progenitors, including hematopoietic cells and hemogenic endothelium [52, 53]. These ³⁹⁰findings and abundance of both BEC subpopulations 10 and 11 in distal human lung warrant 391 further studies to dissect their functions/roles in physiological conditions and chronic lung 392 diseases.

³⁹³To our knowledge, the identification of ageing human lung BEC subpopulations belonging 394 to bronchial or pulmonary circulation or specific lymphatic networks $[19, 20]$, including two 395 subpopulations of "de-differentiated" cells (zero and 5), has not been conducted before our

396 study. These "de-differentiated" BEC subpopulations were present in all nine analysed ageing 397 human lungs from 49-72 years old subjects and belonged exclusively to pulmonary 398 circulation. Findings from our scRNAseq analysis in IPF are in accordance with reports 399 about the plasticity of endothelium and loss of EC identity, frequently associated with Endo-⁴⁰⁰MT in vascular disorders [7, 54-56]. In our study, decreases in EC differentiation scores in 401 three BEC subpopulations (zero, 4 and 7) and one LEC subpopulation (zero) in IPF co-402 occurred with increases in mesenchymal score. These findings suggest that Endo-MT, which 403 has been previously proposed in IPF [56, 57], is also one of the subpopulation-specific 404 features of the ageing human lung endothelium in this disease.

405 Lower average number of genes per cell associated with ageing human lung BEC de-406 differentiation in subpopulations zero and 5 has been also observed in few subpopulations of 407 other cell types within ageing human lung in our study, concordant to findings for individual 408 cell subpopulations identified in scRNAseq studies of ageing tissues from other organs [58, 409 59]. Importantly, subpopulations zero and 5 have comparable levels of the house keeping gene ⁴¹⁰*B2M* and pan-EC marker expression profiles (ridgeplots) to other ageing human lung BEC 411 subpopulations, whilst having a considerably larger proportion of cells with lower expression 412 of *PECAM1* and *CALCRL*. Together with distinct clustering of BEC population, including 413 these two subpopulations, away from the rest of cell populations within the integrated single 414 cell map of ageing human lungs (Figure 1B), these data support the identity of 415 subpopulations zero and 5 as EC. The age-associated de-differentiation of human lung 416 endothelium subpopulations, especially from alveolar regions (BEC sub-populations 3, 4, 6 417 and 8), is the most likely explanation for their "contribution" to subpopulation zero, which 418 contained \sim 30% of BEC in ageing human lungs. Together with pseudotime analysis data 419 demonstrating that subcluster zero potentially act as a convergence "hub" for 7 ⁴²⁰subpopulations of ageing BEC , these findings could serve as an explanation for

⁴²¹immunohistochemistry-based findings in our study and other reports using pan-EC markers

422 and suggesting a loss of vasculature in IPF lung $[10, 60]$.

423 Cell cycle analysis revealed that the majority (over 50%) of the cells in subpopulations 424 zero, 4-7 and 9 in ageing human lung were in S phase. Cell cycle arrest and increase in S ⁴²⁵phase proportion have been linked to cell senescence in studies using *in vivo* or *in vitro* 426 models, including murine lung EC [59, 61]. All nine analysed ageing human lung BEC 427 subpopulations had positive senescence scores, which increased only in two pulmonary ⁴²⁸subpopulations, "de-differentiated capillary" and "aerocyte", in IPF. Senescence has been 429 classified as a hallmark of ageing $[4]$, but remains challenging to analyse in human tissues 430 and EC within any organ. To date, the presence of senescent endothelium has been associated 431 with hypertension and increased cardiovascular disease risk, but not chronic lung diseases or ⁴³²lung circulatory system pathology, in elderly subjects [62-64]. In our study, we report the 433 presence and location of senescent EC in ageing blood vessels within distal lung parenchyma 434 diagnostic biopsy of IPF, warranting further investigation.

435 The age-associated decline in properties of highly specialized EC subpopulations in 436 human lung (de-differentiation due to Endo MT, global reduction in gene expression, and ⁴³⁷senescence) is likely to contribute to alterations of function of individual vessel sub-types 438 comprising respective blood and lymphatic systems. Further exploration is needed into 439 dissecting whether further de-differentiation or senescence $[65]$ in individual subpopulations 440 of IPF endothelium contribute to disease pathophysiology and/or progression and may 441 present further avenues for therapy using drugs targeting these pathways in elderly. 442 Furthermore, although rare, IPF can occur in younger adult populations (11.3 per 100 \Box 000 443 individuals; $[66]$), with a significant paucity of studies investigating the mechanisms of lung 444 fibrosis pathogenesis. The contribution of revealed in our study ageing human lung BEC-445 related processes, and "de-differentiation" in particular, to IPF pathophysiology and 446 susceptibility in young population requires further investigation.

⁴⁴⁷Disease-specific heterogeneity of ageing human lung endothelium in IPF patients ⁴⁴⁸involves changes in the percentage contribution and transcriptional profiles of individual EC ⁴⁴⁹subpopulations. In IPF, observed significant increase in cell numbers in two (bronchial 450 venules IPF Endo 1 and 2) and decrease in one (bronchial capillary) BEC subpopulations is ⁴⁵¹associated with fibrosis, bronchi number and tissue sample location (distal parenchyma or 452 other regions within lung), but accompanied by the lack of significant changes in lymphatic 453 endothelium. These findings for ageing BEC are in accordance with IPF-associated changes 454 for "VE peribronchial" subpopulation, which was identified by conducting analysis of age-455 unmatched lung tissue samples $[25]$. This subpopulation shares a degree of similarity with 456 two subpopulations of ageing human lung BEC identified in our study - IPF Endo 1 and 2, 457 which are transcriptionally distinct and derived from two independent cohorts (Figures 2F, ⁴⁵⁸3D), with only one being from the same scRNAseq dataset as "VE peribronchial" 459 subpopulation. Observed in our study decrease in percentage contribution of total LEC 460 (Figure 1G) or LEC sub-population 2 in cohort 1 (distal lung samples) in IPF was non-⁴⁶¹significant, but concurs with decline observed by others in lymphatic vessel density in distal 462 lung parenchyma in IPF $[9]$. These findings warrant further investigation of the specific ⁴⁶³bronchial BEC and LEC subpopulations as potential cellular targets for therapeutic 464 management in IPF.

465 Changes in transcriptional profiles of individual subpopulations of ageing human lung EC 466 related to key EC-relevant processes suggest their subpopulation-specific functional 467 responses within the fibrotic lung microenvironment and roles in IPF pathophysiology. ⁴⁶⁸Alterations in three pulmonary BEC and one LEC subpopulation in IPF lung included DEG 469 which significantly mapped to IPF pathways. This finding suggests previously unrecognized 470 direct involvement of "de-differentiated", "aerocyte" and "immune marker (low) expressing" 471 BEC (subpopulations zero, 8 and 11 respectively) and LEC subpopulation 1 from ageing 472 human lung in IPF and their potential utility as targets for therapy. Moreover, the association

473 of DEG in one bronchial and three pulmonary BEC subpopulations with fibrotic or 474 inflammatory pathways implies their active roles in IPF progression. Finally, the 475 translocation of IPF Endo 1 subpopulation from the macrovascular to the 476 capillary/microvascular group in IPF suggests a disease-specific shift in its transcriptional 477 phenotype to a capillary/microvascular-like endothelium, which co-occurs with changes to its 478 vascular tone and permeability.

479 Previous studies of lung vasculature in IPF suggest a contribution of increased 480 permeability $[15, 16]$, aberrant angiogenesis $[67]$ and endothelial dysfunction $[17]$ in blood 481 vessels to the fibrotic lung microenvironment and disease progression. Our data show that 482 eight BEC and two LEC subpopulations exhibit decreases in vasodilation scores, with five of 483 these subpopulations (including two bronchial and two pulmonary "de-differentiated" BEC 484 and LEC subpopulation one) also showing reduction in permeability scores in IPF. Two 485 common co-morbidities in IPF are cardiovascular disease and pulmonary hypertension [68, ⁴⁸⁶69], suggesting that systemic as well as lung-specific endothelial dysfunction could be 487 contributing to IPF. Secondary endpoints in a recent clinical trial of the prostacyclin analogue 488 treprostinil via non-systemic delivery (inhalation) to treat IPF patients with pulmonary 489 hypertension, included improved lung function and a decrease in fibrosis progression events 490 compared to placebo $[70, 71]$. These data are intriguing in the context of our findings 491 indicating that pulmonary "de-differentiated" endothelium (subpopulations zero and 5) and 492 the BEC from the "singular alveolar pool" $(3, 4, 6$ and 8) in IPF could be primary cellular 493 targets for inhalation-based therapies affecting expression of genes involved in regulation of ⁴⁹⁴EC identity and vascular tone. Avenues for targeting these and other BEC or LEC ⁴⁹⁵subpopulations, which show changes in vasodilation and permeability scores in IPF, for 496 therapy should be therefore explored/investigated.

⁴⁹⁷To our knowledge, a limited number of studies characterizing individual lymphatic ⁴⁹⁸system networks (and vessel sub-types or LEC composing them) in physiologically ageing or

499 ageing-associated IPF lungs have been conducted to date with main focus on intralobular and 500 sub-pleural lymphatics [9, 11, 20, 26, 46]. Our study revealed 5 distinct sub-populations 501 (based on 20 novel DEG and including three PDPN-positive subpopulations) of LEC, all with 502 statistically unchanged cell numbers and modest changes in gene expression in IPF (101 vs ⁵⁰³3596 DEG, when compared to BEC). The study also uncovered uniform distribution of ⁵⁰⁴PDPN-positive vessels in all tissue regions (bronchial, alveolar and pleural) within ageing 505 human distal lung parenchyma detected using a single diagnostic biopsy of IPF. These 506 findings bridge and substantially expands knowledge available from previous studies $[9, 11,$ 507 26, 39, 40, 45, 46] to include honeycomb cysts. At the same time, this warrants further ⁵⁰⁸annotation and spatial validation of these subpopulation to facilitate dissection of their roles 509 in pathophysiology of IPF and other chronic lung diseases.

510 IPF-associated changes in transcriptional profiles of LEC suggest subpopulation-specific 511 pattern of responses to the fibrotic lung environment (with only 101 DEG in LEC 512 subpopulations compared to 3596 identified for BEC), affecting EC-relevant processes 513 predominantly in LEC from sub-populations zero and two. Transcriptional changes in LEC 514 from ageing lung are likely to account for the alterations in their properties and reported 515 "disappearance" of subpleural and interlobular lymphatics in IPF by others [9]. Furthermore, 516 the network of subpleural lymphatic capillaries drains lymph from the surface of the lung 517 [20] and presents potential route for drug delivery to distal lung tissue affected by fibrotic 518 changes in IPF [72]. Lymphatics have been considered an attractive option for targeted 519 therapy in cancer and should be also exploited for the management of IPF and other chronic 520 lung diseases [73]. Therefore, further investigations of the roles of ageing human LEC in the 521 fibrotic lung environment is warranted.

522 Current therapy for IPF patients aims to slow disease progression and maintain lung 523 function $[74, 75]$. Two medications, nintedanib and pirfenidone, have been approved for the 524 treatment of IPF on the basis of reductions in the rate of physiologic decline, but the disease

525 still progresses in treated patients and there remains no cure [76]. Promising clinical trials 526 such as the recent trial of treprostinil $[70, 71]$ continue to improve the outlook for future 527 therapy. Understanding the properties of individual circulation networks, blood and ⁵²⁸lymphatic EC subpopulations and their altered functions within pre-fibrotic and fibrotic ⁵²⁹microenvironments in IPF lung presents possible avenues for management (halting or 530 reversing progression) of this debilitating and life-threatening disease. IPF endothelium and 531 its individual subpopulations present potential cellular targets for therapy repurposing ⁵³²appropriate anti-fibrotic, -inflammatory or -senescence drugs in IPF, including the 533 possibilities for personalised medicine.

534

⁵³⁵**Conclusions**

536 In summary, our study discovered the phenomenon of the distinct "IPF endothelium" 537 phenotype/state in ageing human lung, which contributes to UIP pattern in IPF. We propose 538 that disease-specific heterogeneity of ageing human lung endothelium (from blood and ⁵³⁹lymphatic vessels) should be considered as a hallmark of IPF. In the future, the exploitation 540 of the knowledge about EC heterogeneity, including properties and functions of individual ⁵⁴¹EC subpopulations, in ageing human lung has the potential in IPF to protect lung function, ⁵⁴²improving patients' quality of life and survival. Our molecular findings should help with 543 building a conceptual framework for appreciating the endothelium in ageing human lung as a 544 significant contributor and a probable target for biomarker development and/or therapy in ⁵⁴⁵IPF, other chronic lung diseases and diseases associated with fibrosis in other organs, 546 including lymphoedema and cancer.

547

⁵⁴⁸**Methods**

549 To characterise ageing human lung endothelium in IPF and to account for its intra- and inter-550 lung heterogeneity (within and between individuals; $[29]$), we conducted the comparative

551 analysis of lung tissues from elderly IPF patients and healthy donors (49-72 years old for 552 both groups) by integrating scRNAseq datasets from two independent cohorts, each 553 composed of age-matched healthy and IPF lung samples $[25, 27]$. We generated integrated 554 single-cell maps of ageing human lung endothelium, identified EC subpopulations and 555 characterised their transcriptional profiles, differences in percentage contribution and gene 556 expression signatures, and also conducted spatial analysis of findings by performing 557 immunohistochemistry and high content microscopy using distal lung diagnostic biopsy of ⁵⁵⁸IPF (with confirmed histopathological pattern of usual interstitial pneumonia). Full details of 559 the methods are provided in Additional file 1: Detailed methods.

⁵⁶¹**Declarations**

⁵⁶³*Ethics approval and consent to participate.* This study utilised publicly available data. 564 Detailed information can be found in the original articles $[25; 27]$. Analysis of surplus human ⁵⁶⁵lung biopsy tissue by immunohistochemistry was approved by the Hull and East Riding 566 Research Ethics Committee (reference 08/H1304/54).

⁵⁶⁸*Consent for publication.* Not applicable.

⁵⁷⁰*Availability of data and materials.* The datasets analysed during the current study are 571 available in gene expression omnibus (GEO). Data from cohort $1 \, [27]$ is available at 572 GSE122960 RAW: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE122960 and in 573 cohort 2 [25] - from GSE136831_RAW: 574 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE136831.

575

⁵⁷⁶*Competing interests.* The authors declare that they have no competing interests.

577

⁵⁷⁸*Funding.* Kate Garthwaite Pulmonary Fibrosis Research Fund; University of Hull Endothelial ⁵⁷⁹Cell Research Fund; University of Hull PhD Scholarships Fund for "Health Global Data 580 Pipeline (Health*GDP) for Biomedical Research and Clinical Applications" cluster; The 581 Anatomical Society.

582

⁵⁸³*Author contributions.* ECF, SPH and LLN contributed to study conception and design. ECF, ⁵⁸⁴AAM and LLN performed bioinformatic analysis. ECF and LLN performed 585 immunohistochemistry staining and image analysis. ECF and LLN analysed and interpreted 586 data. SPH and LLN supervised study execution. ECF and LLN drafted the manuscript. All 587 authors reviewed the manuscript.

⁵⁸⁹*Acknowledgements.* We thank all transplant donors and IPF patients who participated in the 590 several studies analysed in this manuscript and the authors who made scRNAseq datasets 591 publicly available. Mr Collins and Viper HPC Team, Drs Peter O'Toole, Joanne Marrison ⁵⁹²(both from The University of York Biotechnology Facility Team), Professors Adrian Harris, 593 Anthony Maraveyas, Tatsuo Shimosawa and John Greenman, Drs Sarah De Val, Stephen ⁵⁹⁴Henderson, Camille Ettelaie, Markus Queisser, Veronica Carroll, Vicky Green, Mr Matthew 595 Morfitt, Mr Dimitrios Manolis, Mrs Shirin Hasan and Mrs Nicola Briggs for their support.

References

- 597 1. Zaman T, Lee JS. Risk factors for the development of idiopathic pulmonary fibrosis: A review. *Curr Pulmonol Rep* 2018; 7: 118-125.
- 2. Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, Swigris JJ, Taniguchi H, Wells AU. Idiopathic pulmonary fibrosis. *Nat Rev Dis Primers* 2017; 3: 17074.
- 3. Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, Patel H, Kreuter M.
- Global incidence and prevalence of idiopathic pulmonary fibrosis. *Respiratory research* 2021; 22: 1-10.
- 4. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of ageing. *Cell* 2013; 153: 1194-1217.
- 5. Strongman H, Kausar I, Maher TM. Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK. *Advances in therapy* 2018; 35: 724-736.
- 6. Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. *Annu Rev Pathol* 2014; 9: 157-179.
- 7. Gaikwad AV, Lu W, Dey S, Bhattarai P, Chia C, Larby J, Haug G, Myers S, Jaffar J, Westall G, Singhera GK, Hackett TL, Markos J, Eapen MS, Sohal SS. Vascular remodelling in idiopathic pulmonary fibrosis patients and its detrimental effect on lung physiology: potential role of endothelial-to-mesenchymal transition. *ERJ Open Res* 2022; 8.
- 8. Aspelund A, Robciuc MR, Karaman S, Makinen T, Alitalo K. Lymphatic System in Cardiovascular Medicine. *Circ Res* 2016; 118: 515-530.
- 9. Ebina M, Shibata N, Ohta H, Hisata S, Tamada T, Ono M, Okaya K, Kondo T, Nukiwa T. The disappearance of subpleural and interlobular lymphatics in idiopathic pulmonary fibrosis. *Lymphatic research and biology* 2010; 8: 199-207.
- 10. Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M, Sasano H, Kondo T, 621 Nukiwa T. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.03.08.22272025;](https://doi.org/10.1101/2022.03.08.22272025) this version posted April 13, 2023. The copyright holder for this preprint

- pulmonary fibrosis. *American journal of respiratory and critical care medicine* 2004;
- 623 169: 1203-1208.
- 11. El-Chemaly S, Malide D, Zudaire E, Ikeda Y, Weinberg BA, Pacheco-Rodriguez G, 625 Rosas IO, Aparicio M, Ren P, MacDonald SD, Wu HP, Nathan SD, Cuttitta F, McCoy JP, Gochuico BR, Moss J. Abnormal lymphangiogenesis in idiopathic 627 pulmonary fibrosis with insights into cellular and molecular mechanisms. *Proc Natl Acad Sci U S A* 2009; 106: 3958-3963.
- 12. Gaje PN, Stoia-Djeska I, Cimpean AM, Ceausu RA, Tudorache V, Raica M. Lymphangiogenesis as a Prerequisite in the Pathogenesis of Lung Fibrosis. *In vivo* 631 2014; 28: 367-373.
- 13. Glasgow CG, El-Chemaly S, Moss J. Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis. *European Respiratory Review* 2012; 21: 196-206.
- 634 14. Lara AR, Cosgrove GP, Janssen WJ, Huie TJ, Burnham EL, Heinz DE, Curran-Everett D, 635 Sahin H, Schwarz MI, Cool CD. Increased lymphatic vessel length is associated with the fibroblast reticulum and disease severity in usual interstitial pneumonia and nonspecific interstitial pneumonia. *Chest* 2012; 142: 1569-1576.
- 15. Montesi SB, Rao R, Liang LL, Goulart HE, Sharma A, Digumarthy SR, Shea BS, 639 Seethamraju RT, Caravan P, Tager AM. Gadofosveset-enhanced lung magnetic resonance imageing to detect ongoing vascular leak in pulmonary fibrosis. *European Respiratory Journal* 2018; 51.

16. Montesi SB, Zhou IY, Liang LL, Digumarthy SR, Mercaldo S, Mercaldo N, Seethamraju RT, Rosen BR, Caravan P. Dynamic contrast-enhanced magnetic resonance imageing of the lung reveals important pathobiology in idiopathic pulmonary fibrosis. *ERJ open research* 2021; 7; 00907-2020

17. Probst CK, Montesi SB, Medoff BD, Shea BS, Knipe RS. Vascular permeability in the fibrotic lung. *European Respiratory Journal* 2020; 56; 1900100

- 33. Gillich A, Zhang F, Farmer CG, Travaglini KJ, Tan SY, Gu M, Zhou B, Feinstein JA,
- Krasnow MA, Metzger RJ. Capillary cell-type specialization in the alveolus. *Nature* 699 2020; 586: 785-789.
- 34. Herwig N, Belter B, Pietzsch J. Extracellular S100A4 affects endothelial cell integrity and stimulates transmigration of A375 melanoma cells. *Biochemical and Biophysical*
- *Research Communications* 2016; 477: 963-969.
- 35. Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. *J Cell Physiol* 2003; 194: 237-255.
- 36. Nukala SB, Tura-Ceide O, Aldini G, Smolders V, Blanco I, Peinado VI, Castellà M, 706 Barberà JA, Altomare A, Baron G, Carini M, Cascante M, D'Amato A. Protein network analyses of pulmonary endothelial cells in chronic thromboembolic 708 pulmonary hypertension. *Sci Rep* 2021; 11: 5583.
- 37. Ochiya T, Takenaga K, Endo H. Silencing of S100A4, a metastasis-associated protein, in endothelial cells inhibits tumor angiogenesis and growth. *Angiogenesis* 2014; 17: 17- 711 26.
- 38. Vanlandewijck M, He L, Mäe MA, Andrae J, Ando K, Del Gaudio F, Nahar K, Lebouvier T, Laviña B, Gouveia L, Sun Y, Raschperger E, Räsänen M, Zarb Y, Mochizuki N, 714 Keller A, Lendahl U, Betsholtz C. A molecular atlas of cell types and zonation in the brain vasculature. *Nature* 2018; 554: 475-480.
- 39. Sibler E, He Y, Ducoli L, Keller N, Fujimoto N, Dieterich LC, Detmar M. Single-cell 717 transcriptional heterogeneity of lymphatic endothelial cells in normal and inflamed murine lymph nodes. *Cells* 2021; 10: 1371.
- 40. Takeda A, Hollmén M, Dermadi D, Pan J, Brulois KF, Kaukonen R, Lönnberg T, 720 Boström P, Koskivuo I, Irjala H, Miyasaka M, Salmi M, Butcher EC, Jalkanen S. 721 Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell

- 41. Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical Expression of Endothelial Markers CD31, CD34, von Willebrand Factor, and Fli-1 in Normal Human Tissues. *Journal of Histochemistry & Cytochemistry*. 2006;54(4):385-395
- 42. Nikitenko LL, Smith DM, Bicknell R, Rees MC. Transcriptional regulation of the CRLR gene in human microvascular endothelial cells by hypoxia. FASEB J. 2003 729 Aug;17(11):1499-501.
- 43. Nikitenko LL, Blucher N, Fox SB, Bicknell R, Smith DM, Rees MC. Adrenomedullin and CGRP interact with endogenous calcitonin-receptor-like receptor in endothelial 732 cells and induce its desensitisation by different mechanisms. J Cell Sci. 2006;119(Pt 733 5):910-22.
- 44. Nikitenko LL, Leek R, Henderson S, Pillay N, Turley H, Generali D, Gunningham S, 735 Morrin HR, Pellagatti A, Rees MC, Harris AL, Fox SB. The G-protein-coupled 736 receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis. Clin Cancer Res. 738 2013;19(20):5740-8.
- 45. Xiang M, Grosso RA, Takeda A, Pan J, Bekkhus T, Brulois K, Dermadi D, Nordling S, 740 Vanlandewijck M, Jalkanen S, Ulvmar MH, Butcher EC. A Single-Cell 741 Transcriptional Roadmap of the Mouse and Human Lymph Node Lymphatic Vasculature. *Front Cardiovasc Med* 2020; 7: 52.
- 46. Kambouchner M, Bernaudin J-F. Intralobular pulmonary lymphatic distribution in normal human lung using D2-40 antipodoplanin immunostaining. *Journal of Histochemistry & Cytochemistry* 2009; 57: 643-648.
- 47. Bondareva O, Rodríguez-Aguilera JR, Oliveira F, Liao L, Rose A, Gupta A, Singh K, Geier F, Schuster J, Boeckel JN, Buescher JM, Kohli S, Klöting N, Isermann B,

763 at single-cell level. Nat Commun. 2022 Jun 24;13(1):3620.

- ⁷⁶⁴50. Bhatti F, Ball G, Hobbs R, Linens A, Munzar S, Akram R, Barber AJ, Anderson M, ⁷⁶⁵Elliott M, Edwards M. Pulmonary surfactant protein a is expressed in mouse retina by 766 Müller cells and impacts neovascularization in oxygen-induced retinopathy. *Invest* ⁷⁶⁷*Ophthalmol Vis Sci* 2014; 56: 232-242.
- ⁷⁶⁸51. Colmorten KB, Nexoe AB, Sorensen GL. The Dual Role of Surfactant Protein-D in ⁷⁶⁹Vascular Inflammation and Development of Cardiovascular Disease. *Front Immunol* 770 2019; 10: 2264.
- ⁷⁷¹52. Timmermans F, Plum J, Yöder MC, Ingram DA, Vandekerckhove B, Case J. Endothelial progenitor cells: identity defined? J Cell Mol Med. 2009 Jan;13(1):87-102.

- and characterization of endothelial progenitor cells: new approach for finding novel
- 775 markers. Stem Cell Res Ther. 2021 Feb 24;12(1):145.
- 54. Dejana E, Hirschi KK, Simons M. The molecular basis of endothelial cell plasticity. *Nat Commun* 2017; 8: 14361.
- 55. Gaikwad AV, Eapen MS, McAlinden KD, Chia C, Larby J, Myers S, Dey S, Haug G,
- 779 Markos J, Glanville AR. Endothelial to mesenchymal transition (EndMT) and 780 vascular remodeling in pulmonary hypertension and idiopathic pulmonary fibrosis. *Expert Review of Respiratory Medicine* 2020; 14: 1027-1043.
- 56. Piera-Velazquez S, Mendoza FA, Jimenez SA. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of human fibrotic diseases. *Journal of clinical medicine* 2016; 5: 45.
- 57. Jia W, Wang Z, Gao C, Wu J, Wu Q. Trajectory modeling of endothelial-to-mesenchymal 786 transition reveals galectin-3 as a mediator in pulmonary fibrosis. Cell Death Dis. 2021 787 Mar 26;12(4):327
- 58. Durante MA, Kurtenbach S, Sargi ZB, Harbour JW, Choi R, Kurtenbach S, Goss GM, 789 Matsunami H, Goldstein BJ. Single-cell analysis of olfactory neurogenesis and differentiation in adult humans. *Nat Neurosci* 2020; 23: 323-326.
- 791 59. Kumari R, Jat P. Mechanisms of cellular senescence: cell cycle arrest and senescence associated secretory phenotype. *Frontiers in cell and developmental biology* 2021; 9: 793 485.
- 60. Barratt S, Millar A. Vascular remodelling in the pathogenesis of idiopathic pulmonary fibrosis. *QJM: An International Journal of Medicine* 2014; 107: 515-519.
- 61. van Deursen JM. The role of senescent cells in ageing. *Nature* 2014; 509: 439-446.

- ⁷⁹⁷62. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell
- 798 senescence in human atherosclerosis: role of telomere in endothelial dysfunction.
- ⁷⁹⁹*Circulation* 2002; 105: 1541-1544.
- ⁸⁰⁰63. Seals DR, Jablonski KL, Donato AJ. Ageing and vascular endothelial function in humans.
- ⁸⁰¹*Clin Sci (Lond)* 2011; 120: 357-375.
- ⁸⁰²64. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. The ageing endothelium, ⁸⁰³cardiovascular risk and disease in man. *Exp Physiol* 2009; 94: 317-321.
- ⁸⁰⁴65. Ting KK, Coleman P, Zhao Y, Vadas MA, Gamble JR. The ageing endothelium. *Vasc* ⁸⁰⁵*Biol* 2021; 3: R35-R47.
- 806 66. Raghu G, Chen SY, Hou Q, Yeh WS, Collard HR. Incidence and prevalence of idiopathic
- 807 pulmonary fibrosis in US adults 18-64 years old. Eur Respir J. 2016;48(1):179-86.
- 808 67. Barratt SL, Creamer A, Hayton C, Chaudhuri N. Idiopathic pulmonary fibrosis (IPF): an 809 overview. *Journal of clinical medicine* 2018; 7: 201.
- ⁸¹⁰68. Farkas L, Gauldie J, Voelkel NF, Kolb M. Pulmonary hypertension and idiopathic 811 pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. *Am J Respir* ⁸¹²*Cell Mol Biol* 2011; 45: 1-15.
- ⁸¹³69. Hubbard RB, Smith C, Le Jeune I, Gribbin J, Fogarty AW. The association between 814 idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J ⁸¹⁵*Respir Crit Care Med* 2008; 178: 1257-1261.
- 816 70. Nathan SD, Tapson VF, Elwing J, Rischard F, Mehta J, Shapiro S, Shen E, Deng C, 817 Smith P, Waxman A. Efficacy of Inhaled Treprostinil on Multiple Disease 818 Progression Events in Patients with Pulmonary Hypertension due to Parenchymal ⁸¹⁹Lung Disease in the INCREASE Trial. *Am J Respir Crit Care Med* 2022; 205: 198- 820 207.
- ⁸²¹71. Nathan SD, Waxman A, Rajagopal S, Case A, Johri S, DuBrock H, De La Zerda DJ, 822 Sahay S, King C, Melendres-Groves L, Smith P, Shen E, Edwards LD, Nelsen A,

- ⁸²³Tapson VF. Inhaled treprostinil and forced vital capacity in patients with interstitial
- 824 lung disease and associated pulmonary hypertension: a post-hoc analysis of the
- ⁸²⁵INCREASE study. *Lancet Respir Med* 2021; 9: 1266-1274.
- 826 72. Solari E, Marcozzi C, Ottaviani C, Negrini D, Moriondo A. Draining the Pleural Space:
- ⁸²⁷Lymphatic Vessels Facing the Most Challenging Task. *Biology (Basel)* 2022; 11. 419
- 828 73. Zhang XY, Lu WY. Recent advances in lymphatic targeted drug delivery system for 829 tumor metastasis. *Cancer Biol Med* 2014; 11: 247-254.
- 830 74. Maher TM, Strek ME. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to 831 treat. *Respir Res* 2019; 20: 205.
- 832 75. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR,
- ⁸³³Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L,
- 834 Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Schünemann HJ. An
- 835 Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic
- 836 Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. *Am J Respir* ⁸³⁷*Crit Care Med* 2015; 192: e3-19.
- 838 76. Brownell R, Kaminski N, Woodruff PG, Bradford WZ, Richeldi L, Martinez FJ, Collard ⁸³⁹HR. Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis. *Am J*
- ⁸⁴⁰*Respir Crit Care Med* 2016; 193: 1213-1218.
- 841 77. Krämer A, Green J, Pollard Jr J, Tugendreich S. Causal analysis approaches in ingenuity ⁸⁴²pathway analysis. *Bioinformatics* 2014; 30: 523-530.
- 843 78. González-Loyola A, Petrova TV. Development and aging of the lymphatic vascular ⁸⁴⁴system. *Adv Drug Deliv Rev.* 2021;169: 63-78.

845

⁸⁴⁶**Figure legends**

847

⁸⁴⁸**Figure 1. Cell type-specific composition of ageing human lung tissues from donors and** ⁸⁴⁹**IPF patients from two independent cohorts. (A)** Schematic of methodology for samples 850 integration and comprehensive data analysis. Selected data from two studies were grouped 851 into two cohorts (18 samples in total; see Table 1; $[25, 27]$) and subjected to quality control 852 (Additional file 2: Figures S1, 2B) and merging into an integrated Seurat V4 object for 853 subsequent analysis. The resolution was determined using the clustree R package, with 0.5 854 value used for this analysis and throughput the study to avoid over-clustering. Endothelial 855 cell (EC) clusters were identified using pan-endothelial and lymphatic-specific markers. 3192 856 blood vessel endothelial cells (BEC) and 659 lymphatic vessel endothelial cells (LEC) were 857 identified, and sub-clustered for their characterization and comparison in donor and IPF 858 samples. Full details can be found in Additional file 1: Detailed methods. **(B)** UMAP 859 representation of all cells and cell clusters from all 18 samples (pooled). Clusters were 860 numbered, annotated and labelled according to their detected gene markers. Specific details 861 about each cell population can be found in Additional file 2: Figure S2 and Additional file 3, ⁸⁶²Table S1. Two clusters (LEC and BEC) are labelled with a red ellipse. **(C)** Heatmap of top ten 863 differentially expressed genes by cells in the cluster. Each column represents the average 864 expression for a cell, hierarchically grouped by cell type. Gene expression values are scaled 865 from 2 (yellow) to -2 (purple) across rows within each cell type. **(D)** Violin plots and density 866 plots representation of expression data for pan-EC and LEC-specific markers expression in 867 all identified clusters. Density plot expression values are scaled from between 0.04 and 1 ⁸⁶⁸(*yellow –* high expression) to 0 (*purple* – low expression). **(E)** Stacked bar chart of percentage 869 contribution of each cluster to total lung population, split by cohort and condition - donor or 870 fibrosis (IPF). Colour keys for cluster identity is the same as in **B**. Percent contributions of 871 3,192 BEC and 659 LEC to the total cell population in ageing human lung are shown with

⁸⁷²*arrows*. Specific details for each cell population can be found in the Additional file 3: Table 873 S3. **(F)** UMAP representation of all cells and clusters from all 18 samples (pooled), split by 874 condition (donor or fibrosis) and labelled by cluster (top panel), or split by cohort and 875 labelled by condition (*blue* – donor; *red* – fibrosis; bottom panel). **(G)** Box and whiskers plots 876 of EC percentage all cell types in the lung (*left*) or blood or lymphatic endothelial cells (BEC 877 and LEC respectively) from total EC per sample in individual lung samples percentage from 878 all other cell types in individual lung samples (*right*), split by condition (*blue* – donor; *red* – 879 IPF/fibrosis). The lines within the boxes denotes the medians, the 'box' contains the 25th to 880 75th percentiles and the 'whiskers' mark the range of the data. Statistical analysis was done 881 using Shapiro-Wilk test (p=0.162 for donor and p=0.367 for fibrosis) and unpaired t-test (p = 882 0.139). Means \pm standard deviation (2.501 \pm 1.407 for donor and 3.959 \pm 2.388 for fibrosis). 883 UMAP - Uniform Manifold Approximation and Projection.

884

⁸⁸⁵**Figure 2. Cell subtype-specific EC subpopulation composition of ageing human lung** ⁸⁸⁶**blood vessel endothelial cell cluster from donors and IPF patients from two independent** ⁸⁸⁷**cohorts.** To comprehensively decipher transcriptional signatures of ageing human lung blood 888 vessel endothelial cell (BEC) in IPF, we subtracted scRNAseq data for BEC ($n=3192$) from 889 the total lung cell populations from integrated dataset (two cohorts and both conditions, see ⁸⁹⁰Figure 1A), and sub-clustered them. **(A)** UMAP representation of all cells and cell 891 subpopulations from BEC cluster (from all 18 pooled samples) which are presented in the 892 Figure 1. Subpopulations were labelled 0-11 according to their signatures (Additional file 2: 893 Figure S3). Note that, although subpopulations 1, 7 and 8 visually present with two potential 894 subgroups each on this UMAP, each of two subgroups are not significantly different from 895 each other in the described clustering parameters (Additional file 1: Detailed methods). In 896 subpopulation 1, this is likely to be due to the limitations of visualisation of 2D UMAP 897 compared to 3D UMAP, which shows as an individual cluster (see also Figure 2E, Additional

898 file 4: Video S1). In subpopulation 7 and 8, 3D UMAP reveals the shift of one subgroup 899 towards subpopulation zero (see also Figure 2E; Additional file 4: Video S1). **(B)** Heatmap of 900 top 10 differentially expressed genes (DEG) by subpopulation. Each column represents the 901 average expression for a cell, hierarchically grouped by condition (donor or fibrosis) and cell 902 type. Gene expression values are scaled from 2 (yellow) to -2 (purple) across rows within 903 each cell type. Specific details about each cell subpopulation can be found in Additional file 904 2: Figures S3 - 5, and Additional file 3: Table S4. All cell clusters can be separated with high 905 confidence (Additional file 3: Table S5). **(C, D)** The analysis of the top 10 DEG for each 906 subpopulation (120 in total) was performed alongside tests for expression of pan-EC and ⁹⁰⁷LEC markers and using violin plots to test their subpopulation-specific expression for 908 determining their selection for inclusion (or not) in 10 signatures of ageing lung BEC ⁹⁰⁹subpopulations. **(C)** Violin plots of expression of pan-endothelial and LEC markers in 12 910 identified BEC subpopulations. **(D)** Dot plots of 49 genes identified as differentially 911 expressed by the heatmap in B, plotted alongside pan-EC and LEC markers and control genes 912 for comparison, and used in annotation of 12 identified BEC subpopulations (see also 913 annotation summary presented in Figure 4). Note that 39 (marked in red) of 49 identified 914 subpopulation-specific DEG have not been previously assigned as markers of individual ⁹¹⁵generic subpopulations of ageing human lung BEC. **(E)** Representative lineage map in a form 916 of a three-dimensional (3D) UMAP generated by performing trajectory analysis using the R 917 package Slingshot. Plotted lines are trajectories representing predicted relationships between ⁹¹⁸12 identified BEC subpopulations. 3D video can be found Additional file 4: Video S1. **(F)** 919 Table of module scores (Additional file 1: Detailed methods) grouped by references from 920 which reference signatures were derived. Six studies from 2013-2021 include: (i) Gillich et ⁹²¹al., 2019 (ii) Vanlandewijck et al., 2019; (iii) Iso et al., 2013; (iv) Nukala et al., 2021; (v) 922 Ochiya et al., 2014; (vi) Herwig et al., 2016. Abbreviations: aCAP - aerocyte capillary; gCAP 923 - general capillary; large – large vessel; art- artery; CAP1 - capillary 1; CAP2 - capillary 2;

⁹²⁴bronc – bronchial; S vein - systemic vein; P vein - pulmonary vein; Acap - aerocyte capillary; 925 Gcap - general capillary; PeriB – Peribronchial (Note that names given by the authors are 926 preserved). *Coral red* represents a subpopulation with positive score (above 0) for signature, 927 colour intensity is proportional to the score positivity. Additional information is available in 928 Additional file 1: Detailed methods, Annotation of BEC subpopulation. UMAP - Uniform 929 Manifold Approximation and Projection.

⁹³¹**Figure 3. Percentage contributions of blood endothelial cell subpopulations in donors** ⁹³²**and IPF patients**. Quantitative analysis of percentage contribution of cells from each 933 subpopulation to total blood endothelial cell (BEC) population in ageing human lung from 934 healthy donors and IPF patients was conducted using Seurat v4. **(A)** UMAP of BEC split by ⁹³⁵sample condition (donor or fibrosis). **(B)** Table detailing the number of cells per cluster, split 936 by condition. **(C-D)** Stacked bar charts of percentage contribution of each subpopulation to 937 total endothelial cell population split by condition for **(C)** total integrated dataset and **(D)** ⁹³⁸cohort 1 (*left)* and cohort 2 (*right)*. Cell numbers from each individual sample were analysed 939 using Multiple t test. $P < 0.05$ (*) was considered significant. UMAP - Uniform Manifold 940 Approximation and Projection.

941

⁹⁴²**Figure 4. Annotation of subpopulations and relationship between them in donors and** ⁹⁴³**IPF patients.** The profiling of markers of EC sub-types (Figure 2F, Additional file 2: Figures 944 S6, S7, S9), when combined with the expression of pan-EC and LEC markers (Figure 2C-D) 945 and sub-population-specific signatures identified in this study (based on expression pattern of 946 49 DEG; Figures 2D, Additional file 2: Figure S3), lung tissue sample collection locations 947 (Table 1), modules scores of association with bronchial or pulmonary circulatory networks ⁹⁴⁸(Figure 2F, Additional file 2: Figure S9), EC differentiation status (Additional file 2: Figure ⁹⁴⁹S12), IPF-related alterations in cell numbers (Figure 3), high expression of *IL6*, *SELE* and

⁹⁵⁰*ICAM1* [21, 24]; Figure 2D), cell cycle analysis data (Additional file 2: Figure S8) and 951 findings from three-dimensional pseudo-time lineage analysis (Figure 2E, Additional file 4: 952 Video S1), formed the foundation for the annotation of 12 identified ageing human lung BEC 953 subpopulations with distinct transcriptional signatures (Note that in-depth description is 954 provided in Additional file 1: Detailed methods, Annotation of BEC subpopulations). **(A)** 955 Table summarizing the information taken into account for naming/annotating subpopulations, 956 including gene signatures, sample location by cohort, blood vessel circulatory networks 957 (bronchial and pulmonary) and cell numbers (by condition - donor or IPF/fibrosis). $^{\circ}$ Key 958 colour code for subpopulations is the same as in Figures 2 and 3. b Sample location (by</sup> 959 cohort) information corresponds to Table 1. DLP = distal lung parenchyma, LABS = 960 Longitudinal apical to basal segments. ^cCell number dot plots corresponds to data in Figure ⁹⁶¹3. Signature genes include previously reported (blue; n=10) and *de novo* identified in our 962 study genes (red; n=39). **(B)** Dendrogram (cluster tree) and dot plot of subpopulations, based 963 on unsupervised hierarchical clustering of 12 subpopulations of ageing human lung BEC ⁹⁶⁴from integrated total dataset, which was split into two separate objects by condition (donor on 965 the *left* and fibrosis on the *right*). Stratification into two groups termed "capillary" (or ⁹⁶⁶"microvascular") and "macrovascular" is based on distinct clustering of capillary sub-clusters 967 (3, 5, 7 and 8).

⁹⁶⁹**Figure 5. Spatial validation of bronchial blood endothelial subpopulations in distal lung** ⁹⁷⁰**by immunohistochemistry and quantitative high content image analysis. (A-B)** Dotplots 971 of quantitative analysis of percentage contribution of cells from bronchial subpopulation 2 972 and 7 to total blood endothelial cell (BEC) population in ageing human lung from healthy 973 donors (n=4) and IPF patients (n=4) from cohort 1 (Table 1) was conducted using Seurat v4. 974 Donor samples are shown in blue, fibrosis samples in coral red. **(C)** Masson's trichrome and ⁹⁷⁵**(C, F)** immunohistochemical staining for calcitonin receptor like receptor (CLR) was

976 conducted on formalin fixed paraffin embedded (FFPE) tissue sections of distal lung surgical 977 biopsy from a 58-year-old male patient with IPF (with confirmed histopathological pattern of ⁹⁷⁸usual interstitial pneumonia) using our anti-human CLR antibody LN1436 [43]). **(C)** Images 979 of scanned full sections (scalebars represent $5000\mu m$) and two enlarged regions of interest 980 (ROI) 1 and 2 (see full set in Additional file 2: Figure S16; scalebars represent 100 μ m). 981 Yellow dotted line represents peri-bronchial areas (between bronchi and alveolar regions) that 982 were analysed. Black dotted line represents example measurement of width of peri-bronchial 983 area (see Additional file 1: Detailed methods). Dot plots of quantitative analysis of **(D)** peri-⁹⁸⁴bronchial area width and **(E)** number of CLR-positive nuclei from 9 analysed ROI. **(D-E)** ⁹⁸⁵Low degree fibrosis areas are shown in blue, high degree fibrosis areas in red. A cut off of 986 90µm for average peri-bronchial area width was used to determine high (> 90) and lower (< ⁹⁸⁷90) degree fibrosis. Shapiro Wilcoxon normality test and Mann-Whitney U test were used to 988 analyse the data. P values are indicated at the top. Dotplots presenting: **(D)** quantification for 989 peri-bronchial areas width in μ m and **(E)** a number of CLR positive nuclei per mm² (venule 990 nuclei, *left*; capillary nuclei, *right*). **(F)** Two sections (S1 and S2) from the same distal lung 991 biopsy were used for quantitative high content Image J analysis. Individual bronchi were 992 identified within the total section under microscope and selected for downstream analysis 993 (Additional file 1: Detailed methods). Scale bars represent 5000 µm. Indicated with red box 994 and enlarged to the right of each scanned section are two representative examples of bronchi 995 in individual sections (see full set in Additional file 2: Figure S17). Barcharts representing the results of quantitative image analysis of: **(G)** total section areas in mm², **(H)** number of 997 bronchi per section and **(I)** percentage of CLR-positive nuclei in total section; all done for S1 998 and S2 sections. Colours for bronchial venules and capillaries match colours of ageing human 999 lung BEC subpopulations 2 and 7 presented throughout paper (see Figure 4A as an example).

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.03.08.22272025;](https://doi.org/10.1101/2022.03.08.22272025) this version posted April 13, 2023. The copyright holder for this preprint

¹⁰⁰¹**Figure 6. Comparative analysis of numbers of blood endothelial subpopulations in** ¹⁰⁰²**alveolar regions of distal lung in IPF by scRNAseq, immunohistochemistry and** ¹⁰⁰³**quantitative high content imaging. (A)** Dotplot, **(B)** scatterplot and **(C-D)** stacked bar 1004 charts of quantitative analysis of percentage contribution of cells from subpopulations $0, 2, 3$, ¹⁰⁰⁵4, 6 and 8 to total blood endothelial cell (BEC) population in ageing human lung from 1006 healthy donors (n=4) and IPF patients (n=4) from cohort 1 (Table 1) was conducted using 1007 Seurat v4. **(A-B)** Donor samples are shown in blue, fibrosis samples - in coral red. **(B)** ¹⁰⁰⁸Pearson correlation analysis for percentage contribution of subpopulations zero vs 1009 subpopulation two in fibrosis samples. Line of best fit shown by grey dashed line. R -1010 Pearson correlation coefficient. **(C)** Contribution of subpopulation zero and 2 to total BEC 1011 per sample coloured by subpopulation in fibrosis samples. Colours of ageing human lung 1012 BEC subpopulations match those presented throughout paper (see Figure 4A as an example). ¹⁰¹³**(D)** Stacked bar chart showing percentage contribution of BEC subpopulation zero and 1014 combined alveolar BEC subpopulations 3, 4, 6 and 8, when analysed together as a "single" 1015 alveolar pool". Subpopulation zero is coloured by coral red, Subpopulations 3, 4, 6, 8 are 1016 coloured white. Data includes both donor and fibrosis samples. **(E)** Paired 1017 ridgeplots/histograms and dotplots of *PECAM1* expression in donor (left) and fibrosis (right) ¹⁰¹⁸samples from cohort 1 (Table 1) was conducted using Seurat v4. *Top row,* (coral ridgeplot) - ¹⁰¹⁹subpopulation zero *Middle row,* (light grey ridgeplot) - subpopulations 3, 4, 6 and 8 1020 combined, with insert reflecting data for individual subpopulations; with colours of ageing 1021 human lung BEC subpopulations matching those presented throughout paper (see Figure 4A ¹⁰²²as an example).*Bottom row,* (grey ridgeplot) - subpopulations zero, 3, 4, 6 and 8 combined 1023 into a "single alveolar pool". Note that the ridgeplot and dotplot for this pool in IPF patients ¹⁰²⁴(right) representing the *PECAM1* mRNA expression profile in alveolar region in the lung 1025 tissue, with increased number of CLR-negative BEC when compared to donors (left). **(F-H)** ¹⁰²⁶Immunohistochemical staining for CD31 was conducted on formalin fixed paraffin embedded

¹⁰²⁷(FFPE) tissue sections of distal lung surgical biopsy from a 58-year old male patient with IPF ¹⁰²⁸(with confirmed histopathological pattern of usual interstitial pneumonia) using mouse ¹⁰²⁹monoclonal antibody clone JC/70A. **(F)** Two representative regions of interest (ROI; 1 and 2) 1030 of alveolar regions of distal lung that were used for quantification are presented (see full set ¹⁰³¹in Additional file 2: Figure S18). *Left,* low degree fibrosis, *right,* high degree fibrosis. 1032 Scalebar represents 100 μ m. Black dashed line represents example measurement of width of ¹⁰³³alveolar area analysed (for full details, see Additional file 1: Detailed methods). Dot plots of ¹⁰³⁴quantitative analysis of **(G)** alveolar area thickness in µm and **(H)** proportion of CD31 1035 positive nuclei per mm2 (left) and average DAB signal intensity per CD31 positive nuclei ¹⁰³⁶(right). Nonfibrotic alveoli samples are shown in blue and fibrotic alveoli samples - in coral 1037 red. Nine ROIs were analysed for both nonfibrotic and fibrotic alveoli. Statistical analysis 1038 was done using Shapiro Wilcoxon test and Mann-Whitney U test. P values are indicated at 1039 the top. Note that immunohistochemistry and quantitative high content imaging profiles **(H)** 1040 confirm those from scRNAseq data analysis (E).

1041

¹⁰⁴²**Figure 7. Association of differentially expressed genes in ageing human lung blood** ¹⁰⁴³**vessel endothelial cell with specific signalling pathways and endothelial cell-relevant** ¹⁰⁴⁴**processes in IPF. (A)** An example of volcano plot of differentially expressed genes (DEG) ¹⁰⁴⁵(donor vs IPF/fibrosis) in blood endothelial cell (BEC) subpopulation zero. Volcano plots for 1046 other subpopulations can be found in the Additional file 2: Figure S19A. Statistical analysis 1047 was done using Shapiro Wilcoxon test and Wilcoxon rank sum test, with P value < 0.05 ¹⁰⁴⁸(dotted line indicates cut-off) considered significant. **(B)** Doughnut plot of DEG between 1049 donor and IPF/fibrosis for each subpopulation. Outer ring shows up-regulated genes and 1050 inner ring represents down-regulated genes, with table in the centre showing numbers of ¹⁰⁵¹DEG per subpopulation. Clusters 9 and 10 were excluded from the analysis, as they contained 1052 too few cells to analyse between conditions. **(C)** Bar chart detailing the results of the

¹⁰⁵³Ingenuity Pathway Analysis (IPA) using Core expression analysis function [77] of 1054 statistically significant altered pathways using DEG from **B**. *Blue colour* represents a 1055 negative Z score (down), and *orange* represents a positive Z score (up). DEG from three 1056 subpopulations (4, 6 and 7) did not significantly associate with any pathways and from two 1057 others (9 and 10) had too few cells in the IPF group for analysis. IPA was performed as 1058 described in Additional file 1: Detailed methods. **(D, E)** Key colour code for subpopulations 1059 is the same as in panel **C** and in Figures 2-4. **(D)** Histograms (ridgeplot) of endothelial cells 1060 differentiation (n= 5), mesenchymal transition (n= 12), inflammation (n= 567), and 1061 vasodilation (n= 36) scores in all blood endothelial subpopulations in donors (*donor*) and IPF ¹⁰⁶²(*fibrosis*). Ridgeplots for senescence (n= 79), apoptosis (n= 161), proliferation (n= 54), 1063 migration (n= 175), angiogenesis (n= 48), and permeability (n= 40) can be found in ¹⁰⁶⁴Additional file 2: Figure S20. Number of genes in sets are indicated in brackets. Black dotted ¹⁰⁶⁵line is added to annotate zero (cut-off point for differences). **(E)** Table detailing the P values 1066 for difference in module scores between donor and fibrosis. *Blue* colour represents down-1067 regulation and *orange* - up-regulation in IPF. Statistical analysis was done using Shapiro ¹⁰⁶⁸Wilcoxon test and Mann-Whitney U test. UMAP - Uniform Manifold Approximation and 1069 Projection.

1070

Figure 8. Cell subtype-specific composition of ageing human lung lymphatic endothelial cell cluster from donors and IPF patients from two independent cohorts. To comprehensively decipher transcriptional signatures of ageing human lung lymphatic vessel endothelium in IPF, we subtracted scRNAseq data for ageing human lung lymphatic vessel 1075 endothelial cell (LEC) (n=659) from the total lung cell populations from integrated dataset (two cohorts and both conditions, see Figure 1A), and sub-clustered them. **(A)** *Top,* UMAP 1077 representation of all cells from total LEC cluster/population (from all 18 pooled samples; Figure 1) with pseudotime lineage analysis of 5 resulting subclusters. *Bottom*, UMAP of LEC

1079 clusters coloured by cohort. Clusters were labelled 0-4 according to their signatures, which 1080 are presented as (B) heatmap of top 5 differentially expressed genes by cluster. Full details 1081 about each cell sub-population can be found in Additional file 2: Figure S21-23. **(C)** Violin 1082 plots demonstrating expression of pan-EC markers and LEC-specific genes (*PROX1*, *PDPN*, ¹⁰⁸³*LYVE-1* and *FLT4*) and *CCL21* [78] was done to confirm the identities of all cell ¹⁰⁸⁴subpopulations as LEC. **(D)** Table summarizing the information for each subpopulation, ¹⁰⁸⁵including gene signature (including previously reported, in *blue*, and *de novo* identified in our 1086 study, in *red*, genes), sample location by cohort and cell numbers. ^a Key colour code for 1087 subpopulations is the same as in Figure 8A. b Sample location (by cohort) information</sup> 1088 corresponds to Table 1. DLP = distal lung parenchyma, LABS = Longitudinal apical to basal 1089 segments. ^c Cell number dot plots correspond to data in Additional file 2: Figure S24 A, B. ¹⁰⁹⁰**(E)** Dotplot of quantification for percentage contribution of subpopulation 1 and 2 to total ¹⁰⁹¹LEC per sample. *Left,* subpopulation 1, *right,* subpopulation 2. Donor samples are shown in 1092 blue, fibrosis samples - in coral red. **(F-H)** Immunohistochemical staining for PDPN was 1093 conducted on formalin fixed paraffin embedded (FFPE) tissue sections of distal lung surgical ¹⁰⁹⁴biopsy from a 58-year-old male patient with IPF (with confirmed histopathological pattern of ¹⁰⁹⁵usual interstitial pneumonia) using mouse monoclonal antibody clone D2-40. **(F)** Image of 1096 scanned full section (scalebars represent 5000µm), with six regions of interest (ROI) 1-6 1097 labelled with red boxes and shown enlarged in (G) (scalebars represent 100 μ m). Table insert 1098 to the right is the summary of information for each ROI on whether observed structure could 1099 be identified in original publications for cohorts 1 and 2 $($ ^{*} - $[25, 27]$), i.e. DLP and LABS 1100 areas of the lung respectively (see **D**), and which LEC subpopulations were detected in our 1101 analysis (see A). **(G)** |Representative images for each ROI (magnified from **F**; scalebars 1102 represent 100µm), including inserts (red dotted boxes) of the areas containing PDPN-positive ¹¹⁰³lymphatic vessels (*bottom right;* scalebars represent 100µm). Coloured squares in the top left 1104 corner correspond to mapping conducted using table presented in (F) . Arrows - lymphatic

TABLES

It is made available under a CC-BY-NC-ND 4.0 International license . medRxiv preprint doi: https://doi.org/10.1101/2022.03.08.22272025; this version posted April 13, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted m

TABLES

medRxivpreprint doi: https://doi.org/10.1101/2022.03.08.22272025; this version posted April 13, 2023. The copyright holder for this preprint
 Table 1. Characteristics of aging the wine wine wine samples spinted TABLES

Transferred River preprint doi: https://doi.org/10.1101/2022.03.08.22272025; this version posted April 13, 2023. The copyright holder for this preprint

Table 1. Characteristics of aging fit materiality was from G **TABLES**

Table 1. Characteristics of aging the sumplisheed April 13, 2023. The copyright holder for this preprint

Table 1. Characteristics of aging the male, all and the sumption of the sumplicable to display the prepri applicable.

medRxiv preprint doi: [https://doi.org/10.1101/2022.03.08.22272025;](https://doi.org/10.1101/2022.03.08.22272025) this version posted April 13, 2023. The copyright holder for this preprint
- which was not certified by peer review) is the author/funder, who has granted A

Which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the

Little made available under a CC-BY-NC-ND-4.0 International license

Little made available under a CC-BY-NC Condition Identity 11 Condit Donor Fibrosis 5 8 Identity 1 $UNAP_2$ 7 4 $\frac{10}{2}$ -6678911 8 6 0 9 7 Expression 2 1 $UMAP_1$

ROI 1 ROI 2 ROI 1 ROI 2 ROI 1 ROI 2

A (which was not certified by peer review) is the author/tunder, who has granted media to discuss the control of the control isometr

medRxiv preprint doi: [https://doi.org/10.1101/2022.03.08.22272025;](https://doi.org/10.1101/2022.03.08.22272025) this version posted April 13, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted m

E and the state of the state of the state of the

-0.05 0 0.05 0.10 0.15 -0.05 0 0.05 0.10 0.15 -0.25 0 0.25 0.50 -0.4 -0.2 0 0.2 0.4

4 | NS | NS | NS | 0.007 | 0.0477 | NS | NS | NS | NS | NS

 $= 0$ $= 1$ $= 2$ $= 3$ $= 4$